Sign In
Buy IONS
$55.07
+0.580 (+1.06%)
At Close: Aug 04, 2026
– First presentation of pivotal results showing significant reduction in triglycerides and substantial reduction in acute pancreatitis events in patients with rare, life-threatening disease, for w
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
11:41am, Thursday, 14'th Mar 2024
Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.
Are These 5 Undervalued Stocks Ready to Break Out?
09:11am, Friday, 08'th Mar 2024
Albemarle Corp. NYSE: ALB, Ionis Pharmaceuticals Inc. NASDAQ: IONS, Insulet Corp. NASDAQ: PODD, Hess Corp. NYSE: HES and Wynn Resorts Ltd. NASDAQ: WYNN are among undervalued stocks that beat analysts
Ionis to present at upcoming investor conferences
07:05am, Wednesday, 28'th Feb 2024
CARLSBAD, Calif. , Feb. 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: TD
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
11:30am, Thursday, 22'nd Feb 2024
Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates.
Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Wednesday, 21'st Feb 2024
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wal
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
09:05am, Wednesday, 21'st Feb 2024
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.37 per share a year ago.
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease
06:51am, Friday, 16'th Feb 2024
FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
Ionis Pharmaceuticals (IONS) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:20am, Thursday, 15'th Feb 2024
Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of i
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:06am, Wednesday, 14'th Feb 2024
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication
11:45am, Friday, 09'th Feb 2024
The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Ionis to hold fourth quarter and full year 2023 financial results webcast
07:05am, Wednesday, 07'th Feb 2024
Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
02:26pm, Tuesday, 23'rd Jan 2024
Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
02:12pm, Friday, 29'th Dec 2023
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a
3 Stocks to Buy Now Before They Become Tomorrow's Trillion-Dollar Companies
01:30pm, Wednesday, 27'th Dec 2023
Heading into 2024, the future of the U.S. economy remains uncertain, with conflicting predictions about the possibility of a recession. While some experts anticipate a soft landing, others predict a m
